Vitae Pharmaceuticals (VTAE) : During the past 4 weeks, traders have been relatively bearish on Vitae Pharmaceuticals (VTAE), hence the stock is down -14.75% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.09% relative to the S&P 500. The 4-week change in the price of the stock is -13.87% and the stock has fallen -1.03% in the past 1 week.
The stock has recorded a 20-day Moving Average of 14.42% and the 50-Day Moving Average is 16.09%. Vitae Pharmaceuticals (NASDAQ:VTAE): stock turned positive on Friday. Though the stock opened at $8.53, the bulls momentum made the stock top out at $8.75 level for the day. The stock recorded a low of $8.25 and closed the trading day at $8.63, in the green by 0.35%. The total traded volume for the day was 774,461. The stock had closed at $8.6 in the previous days trading.
The company Insiders own 14.8% of Vitae Pharmaceuticals shares according to the proxy statements. Institutional Investors own 73.19% of Vitae Pharmaceuticals shares. Also, In the latest statement by the brokerage house, JMP Securities downgrades its outlook on Vitae Pharmaceuticals (NASDAQ:VTAE). The current rating of the shares is Market Perform, according to the research report released by the firm. Previously, the company had a rating of Outperform. The rating by the firm was issued on August 4, 2016.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.